Observational study evaluates progression-free survival with maintenance endocrine therapy in metastatic breast cancer, suggesting important implications for treatment.
The benefit of endocrine therapy (ET) as maintenance treatment after chemotherapy (CT) in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) remains unclear. This study aimed to evaluate progression-free survival (PFS) associated with ET as maintenance therapy after CT in patients previously treated with ET, with or without CDK4/6 inhibitors (CDKi).
No takes yet. Share an insight, caveat, or question.
Nannini et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: